Aldeyra Therapeutics Hosts Webcast and Conference Call to Present Second Quarter 2022 Financial Results and Discuss Recent Business Highlights
LEXINGTON, Mass., July 29, 2022–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call at 8:00 a.m. ET on Friday, August 5, 2022 to present its financial results for the quarter ended June 30, 2022 and discuss facts recent company highlights.
The dial-in numbers are (844) 200-6205 for domestic callers and (929) 526-1599 for international callers. The access code is 908644. A live audio webcast of the conference call will also be accessible from the “Investors and Media” section of Aldeyra’s website at https://ir.aldeyra.com /.
After the live webcast, the event will remain archived on the Aldeyra website for 90 days.
About Aldeyra
Aldeyra is a clinical-stage biotechnology company developing innovative therapies designed to treat immune-mediated diseases. Our approach is to discover pharmaceuticals that modulate immune systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways while minimizing toxicity. Two of our lead product candidates, reproxalap and ADX-629, target pre-cytokines, systemic mediators of inflammation known as RASPs (reactive aldehyde species). Reproxalap is in late-stage clinical trials in patients with dry eye disease and allergic conjunctivitis. ADX-629, an orally administered RASP modulator, is in Phase 2 clinical trials for the treatment of systemic immune-mediated diseases. Our pipeline also includes ADX-2191 (0.8% intravitreal methotrexate), in development for the prevention of proliferative vitreoretinopathy and the treatment of retinitis pigmentosa and primary vitreoretinal lymphoma. For more information, visit https://www.aldeyra.com/ and follow us on LinkedIn, Facebook and Twitter.
See the source version on businesswire.com: https://www.businesswire.com/news/home/20220728005954/en/
contacts
Investor & Media:
Scott Solomon
Sharon Merrill Associates, Inc.
Tel: (857) 383-2409
[email protected]
